

# ARGENICA ANNOUNCES NEW APPOINTMENT TO THE BOARD OF DIRECTORS

**Perth, Australia; 2 DECEMBER 2024** - Argenica Therapeutics Limited (ASX: AGN) (“Argenica” or the “Company”), a biotechnology company developing novel therapeutics to reduce brain tissue death after stroke and other neurological conditions, today announced the appointment of Dr Jeannie Joughin as non-executive director.

Dr Joughin brings extensive pharmaceutical industry experience, including senior executive leadership roles in large global organisations in both Australia and the United States. She has directed both in and out licensing of products, growth and commercialisation strategies across small to large cap companies and has built extensive strategic alliances and investment networks which will assist the transition and growth of Argenica as a pharmaceutical development company.

Dr Joughin’s early career included diverse roles across several therapeutic areas including oncology, cardiovascular and neurology. She spent several years in product launch and commercialisation for Bristol-Myers Squibb, Marketing Manager for Mayne Pharma before moving to CSL Biotherapies (now Sequiris) as Director, Pharmaceuticals Marketing & Business Development in 2005. In 2010, Dr Joughin was appointed Vice President, Business Development at CSL Behring in the United States leading the company’s business development to evaluate and execute strategic alliances, divestures, acquisitions, product licensing, and she negotiated major contracts in the United States, Europe and the Asia/Pacific region. In 2015, Dr Joughin took on the role of Executive Vice President and Chief Commercial Officer of the US based Enable Injections Inc. with direct responsibility for the growth of its worldwide business and its successful capital raises.

Returning to Australia, Dr Joughin served as non-executive director on 2 private company boards, held the position of COO for an ASX biotech and joined the venture capital fund, OneVentures, in 2021. She currently serves on various boards including Immuron (ASX:IMC) and private companies including BiVACOR Inc. and ImmVirX Pty Ltd as a non-executive director. Dr Joughin holds a B.Sc (Hons) and Ph.D and is a Graduate of the Australian Institute of Company Directors.

**Argenica Chair, Di Angus commented,** “Jeannie brings deep pharmaceutical business executive expertise, notably in the preparation of assets for commercialisation and extensive business development. Her background in creating and shaping business models, passion for technical advancement and strong credentials in team leadership will be important for Argenica as we work to position the company as an innovative neurology pharmaceutical

development company. On behalf of the board, I am delighted to welcome Jeannie to Argenica”.

*This announcement has been approved for release by the Board of Argenica*

For more information please contact: [info@argenica.com.au](mailto:info@argenica.com.au)

## **ABOUT ARGENICA**

Argenica (ASX: AGN) is developing novel therapeutics to reduce brain tissue death after stroke and other types of brain injury and neurodegenerative diseases to improve patient outcomes. Our lead neuroprotective peptide candidate, ARG-007, has been successfully demonstrated to improve outcomes in pre-clinical stroke models, traumatic brain injury (TBI) and hypoxic ischaemic encephalopathy (HIE). The Company has completed a Phase 1 clinical trial in healthy human volunteers to assess the safety and tolerability of a single dose of ARG-007. Argenica has now initiated a Phase 2 clinical trial in acute ischaemic stroke patients, as well as continuing to generate preclinical data in other neurological conditions.